Trial · NCT01707472
Results by group30
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 30
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Experiencing Treatment-Emergent Adverse Events | Simtuzumab in HIV Participants | 100 | percentage of participants | ||
| Percentage of Participants Experiencing Treatment-Emergent Adverse Events | Simtuzumab in HCV Participants | 100 | percentage of participants | ||
| Percentage of Participants Experiencing Treatment-Emergent Adverse Events | Simtuzumab in HIV/HCV Co-Infected Participants | 100 | percentage of participants | ||
| Number of Participants With a Change From Baseline in Ishak Fibrosis Stage Score at Week 24 | Simtuzumab in HIV Participants | Fibrosis improved: -2 | 0 | Participants | |
| Number of Participants With a Change From Baseline in Ishak Fibrosis Stage Score at Week 24 | Simtuzumab in HCV Participants | Fibrosis improved: -2 | 1 | Participants | |
| Number of Participants With a Change From Baseline in Ishak Fibrosis Stage Score at Week 24 | Simtuzumab in HIV/HCV Co-Infected Participants | Fibrosis improved: -2 | 0 | Participants | |
| Number of Participants With a Change From Baseline in Ishak Fibrosis Stage Score at Week 24 | Simtuzumab in HIV Participants | Fibrosis improved: -1 | 1 | Participants | |
| Number of Participants With a Change From Baseline in Ishak Fibrosis Stage Score at Week 24 | Simtuzumab in HCV Participants | Fibrosis improved: -1 | 1 | Participants | |
| Number of Participants With a Change From Baseline in Ishak Fibrosis Stage Score at Week 24 | Simtuzumab in HIV/HCV Co-Infected Participants | Fibrosis improved: -1 | 0 | Participants | |
| Number of Participants With a Change From Baseline in Ishak Fibrosis Stage Score at Week 24 | Simtuzumab in HIV Participants | Fibrosis did not change: 0 | 2 | Participants | |
| Number of Participants With a Change From Baseline in Ishak Fibrosis Stage Score at Week 24 | Simtuzumab in HCV Participants | Fibrosis did not change: 0 | 4 | Participants | |
| Number of Participants With a Change From Baseline in Ishak Fibrosis Stage Score at Week 24 | Simtuzumab in HIV/HCV Co-Infected Participants | Fibrosis did not change: 0 | 5 | Participants | |
| Number of Participants With a Change From Baseline in Ishak Fibrosis Stage Score at Week 24 | Simtuzumab in HIV Participants | Fibrosis worsened: 1 | 0 | Participants | |
| Number of Participants With a Change From Baseline in Ishak Fibrosis Stage Score at Week 24 | Simtuzumab in HCV Participants | Fibrosis worsened: 1 | 0 | Participants | |
| Number of Participants With a Change From Baseline in Ishak Fibrosis Stage Score at Week 24 | Simtuzumab in HIV/HCV Co-Infected Participants | Fibrosis worsened: 1 | 2 | Participants | |
| Number of Participants With a Change From Baseline in Ishak Fibrosis Stage Score at Week 24 | Simtuzumab in HIV Participants | Fibrosis worsened: 2 | 0 | Participants | |
| Number of Participants With a Change From Baseline in Ishak Fibrosis Stage Score at Week 24 | Simtuzumab in HCV Participants | Fibrosis worsened: 2 | 0 | Participants | |
| Number of Participants With a Change From Baseline in Ishak Fibrosis Stage Score at Week 24 | Simtuzumab in HIV/HCV Co-Infected Participants | Fibrosis worsened: 2 | 1 | Participants | |
| Change From Baseline in HVPG at Week 24 | Simtuzumab in HIV Participants | 2 | Standard Deviation 2.4 | mm Hg | |
| Change From Baseline in HVPG at Week 24 | Simtuzumab in HCV Participants | 0 | Standard Deviation 3.4 | mm Hg |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01707472/results